(1,1,2,2-tetramethylpropyl)ammonium chloride | 29772-64-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (1,1,2,2-tetramethylpropyl)ammonium chloride
• 英文别名: 2,3,3-trimethylbutan-2-amine hydrochloride；1,1,2,2-tetramethyl-propylamine; hydrochloride；(1,1,2,2-Tetramethylpropyl)amine hydrochloride；2,3,3-trimethylbutan-2-amine;hydrochloride
• CAS: 29772-64-3
• 化学式: C₇H₁₇N*ClH
• 分子量: 151.68
• InChiKey: VBLHYILVPSSTFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.19
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1,1,2,2-tetramethylpropyl)ammonium chloride 在 氢氧化钾 、 五氯化磷 作用下， 以 various solvent(s) 为溶剂， 反应 77.0h， 生成 tris(dimethylamino)(1,1,2,2-tetramethylpropylimino)phosphorane
  参考文献：
  名称：

  Schwesinger, Reinhard; Willaredt, Juergen; Schlemper, Helmut, Chemische Berichte, 1994, vol. 127, # 12, p. 2435 - 2454

  摘要：

  DOI：

文献信息

• Method of treating arthritic disease
  申请人：American Cyanamid Company

  公开号：US04269832A1

  公开（公告）日：1981-05-26

  This disclosure describes compositions of matter useful as anti-inflammatory agents and as inhibitors of the progressive joint deterioration characteristic of arthritic disease and the methods of meliorating inflammation and of inhibiting joint deterioration in mammals therewith, the active ingredients of said compositions of matter being certain 2-(substituted-amino)-4,6-bis(alkylamino)-s-triazines.

  本公开说明了一些物质组成，作为抗炎剂和抑制关节退化特征的关节炎疾病的进展的抑制剂，并描述了使用这些物质组成物来改善哺乳动物的炎症和抑制关节退化的方法，该物质组成物的活性成分是某些2-（取代氨基）-4,6-双（烷基氨基）-s-三嗪。
• 2,4,6-Tris-(substituted-amino)-S-triazines, process for their preparation and pharmaceutical compositions containing them
  申请人：AMERICAN CYANAMID COMPANY

  公开号：EP0005586A1

  公开（公告）日：1979-11-28

  The present invention provides a novel 2,4,6-tris- (substituted-amino)-s-triazines which are useful in medicine, more especially as anti-inflammatory agents and as inhibitors of the progressive joint deterioration characteristic of arthritic disease. The compounds of the invention may be represented by the formula: or a pharmaceutically acceptable acid-addition or quaternary ammonium salt thereof; wherein R, is alkylamino having from 4 to 8 carbon atoms, inclusive, 1-adamantyl-amino, 2-adamantylamino, exo [2.2.1] norbornylamino, endo- [2.2.1] norbornylamino, 3-azabicyclo [3.2.1.] octyl, 1,8,8-trimethyl-3-azabicyclo [3.2.1] octyl, 3-azabicyclo [3.3.1] -nonyl, 9-azabicyclo [3.3.1] nonyl, 2-azabicyclo [3.2.2] -nonyl, 3-azabicyclo [3.2.2] -nonyl or endo-3-hydroxy-8-azabicyclo [3.2.1] oct-8-yl; R2 is 1-adamantylamino, 2-adamantylamino, exo [2.2.1] norbornylamino, endo- [2.2.1] norbornylamino, 3-azabicyclo [3.2.1] octyl, 1,8,8-trimethyl-3-azabicyclo [3.2.1] octyl, 3-azabicyclo [3.3.1] -nonyl, 9-azabicyclo [3.3.1] nonyl, 2-azabicyclo [3.2.2] -nonyl, 3-azabicyclo [3.2.2] nonyl or endo-3-hydroxy-8-azabicyclo [3.2.1] oct-8-yl; R3 is hydrogen or alkyl having up to 4 carbon atoms; R4 is 2-(2-pyridyl)ethyl, alkyl having from 4 to 8 carbon atoms, inclusive, phenyl, monohalo(F, Cl, Br)phenyl, 1-adamantyl, 2-adamantyl, ex- o[2.2.1]norbornyl, endo[2.2.1]norbornyl or a monovalent moiety of the formula: wherein Q is a divalent moiety of the formulae: Rs is alkyl having up to 4 carbon atoms, R6 is alkyl having up to 4 carbon atoms or R5 and R6 taken together with their associated N(itrogen) is piperidino, morpholino, pyrrolidino or thiomorpholino; with the proviso that when R4 is alkyl, adamantyl or norbornyl then R3 must be hydrogen; or R3 and R4 taken together with their associated N(itrogen) is 3-azabicyclo [3.2.1] -octyl, 1,8,8-trimethyl-3-azabicyclo [3.2.1] cotyl, 3-azabicyclo [3.2.1] nonyl, 9-azabicyclo [3.3.1] nonyl, 2-azabicyclo [3.2.2] nonyl, 3-azabicyclo [3.2.2] nonyl, endo-3-hydroxy-8-azabicyclo [3.2.1] oct-8-yl, pyrrolidino, piperidino, hexamethyleneimino, heptamethyleneimino or a monovalent moiety of the formula: wherein R is hydrogen, alkyl having up to 4 carbon atoms, phenyl, p-methoxyphenyl or carboalkoxy having up to 4 carbon atoms.

  本发明提供了一种新型的 2,4,6-三-（取代-氨基）-s-三嗪类化合物，该化合物可用于医药，特别是作为抗炎剂和关节炎疾病特有的关节逐渐退化的抑制剂。本发明的化合物可由式表示： 或其药学上可接受的酸加成盐或季铵盐；其中 R，是具有 4 至 8 个碳原子的烷基氨基，包括 1-金刚烷基氨基、2-金刚烷基氨基、外[2.2.1]降冰片烷基氨基、内[2.2.1]降冰片烷基氨基、3-氮杂双环[3.2.1.] 辛基，1,8,8-三甲基-3-氮杂双环 [3.2.1] 辛基，3-氮杂双环 [3.3.1] 壬基，9-氮杂双环 [3.3.1] 壬基，2-氮杂双环 [3.2.2]-壬基、3-氮杂双环[3.2.2]-壬基或内向-3-羟基-8-氮杂双环[3.2.1]辛-8-基；R2 是 1-金刚烷基氨基、2-金刚烷基氨基、外向 [2.2.1]降冰片酰胺基、内[2.2.1]降冰片酰胺基、3-氮杂双环[3.2.1]辛基、1,8,8-三甲基-3-氮杂双环[3.2.1]辛基、3-氮杂双环[3.3.2.1]壬基、9-氮杂双环[3.3.1]壬基、2-氮杂双环[3.2.2]壬基、3-氮杂双环[3.2.2]壬基或内-3-羟基-8-氮杂双环[3.2.1]辛-8-基；R3 是氢或最多具有 4 个碳原子的烷基；R4 是 2-(2-吡啶基)乙基、具有 4 至 8 个碳原子的烷基（包括 4 个）、苯基、单卤代(F、Cl、Br)苯基、1-金刚烷基、2-金刚烷基、前邻[2.2.1]降冰片烷基、内邻[2.2.1]降冰片烷基或式中的一价分子： 其中 Q 是式中的二价分子： Rs 是具有多达 4 个碳原子的烷基，R6 是具有多达 4 个碳原子的烷基，或 R5 和 R6 连同它们的相关 N（它基）是哌啶基、吗啉基、吡咯烷基或硫代吗啉基；但当 R4 是烷基、金刚烷基或降冰片基时，R3 必须是氢；或 R3 和 R4 连同它们的相关 N（它基）是 3- 氮杂双环 [3.2.1]辛基、1,8,8-三甲基-3-氮杂双环[3.2.1]子基、3-氮杂双环[3.2.1]壬基、9-氮杂双环[3.3.1]壬基、2-氮杂双环[3.2.2]壬基、3-氮杂双环[3.2.2]壬基、内-3-羟基-8-氮杂双环[3.2.1]辛-8-基、吡咯烷基、哌啶基、六亚甲基亚氨基、七亚甲基亚氨基或式中的一价分子： 其中 R 是氢、最多 4 个碳原子的烷基、苯基、对甲氧基苯基或最多 4 个碳原子的羧基烷氧基。
• Compounds
  申请人：TMEM16A Limited

  公开号：US11364246B2

  公开（公告）日：2022-06-21

  Compounds of general formula (I): wherein R1, R2, R3, R4, R5a, R* X1, X2, Z and Y are as defined herein are positive modulators of the calcium-activated chloride channel (CaCC), TMEM16A. The compounds are useful for treating diseases and conditions affected by modulation of TMEM16A, particularly respiratory diseases and conditions.

  通式（I）：其中 R1、R2、R3、R4、R5a、R* X1、X2、Z 和 Y 如本文所定义的化合物是钙激活氯通道（CaCC）TMEM16A 的正调节剂。这些化合物可用于治疗受 TMEM16A 调节影响的疾病和病症，特别是呼吸系统疾病和病症。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：ENTERPRISE THERAPEUTICS LTD

  公开号：WO2019145726A9

  公开（公告）日：2019-09-12
• COMPOUNDS
  申请人：Enterprise Therapeutics Limited

  公开号：EP3743406A1

  公开（公告）日：2020-12-02